**UNITED STATES**
**SECURITIES AND EXCHANGE COMMISSION**
**Washington, D.C. 20549**

# FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of November 2026**

Commission File Number: **001-39777**

**Nanobiotix S.A.**
(Translation of registrant's name into English)

**60 Rue de Wattignies 75012 Paris, France**
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]  Form 40-F [ ]

On November 12, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(c) Exhibit 99.1. Press release dated November 12, 2026

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Nanobiotix S.A.**
(Registrant)

Date: November 12, 2026

/s/ Brandon Owens
Brandon Owens
Vice President, Strategic Marketing and Corporate Communications

**EXHIBIT 99.1**

# Voting Rights and Shares Capital of the Company

***In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)***

PARIS, Nov. 12, 2026 (GLOBE NEWSWIRE) --
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com

| Date | Number of Shares Outstanding | Total number of voting rights | |
|---|---|---|---|
| | | Total voting rights, theoretical[1] | Total voting rights, exercisable[2] |
| October 31, 2026 | 50,968,893 | 54,726,179 | 54,704,061 |

**About NANOBIOTIX**

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company's philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has a subsidiary in Cambridge, Massachusetts (United States).

Nanobiotix is the owner of more than 30 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.

---

[1] *The total number of theoretical (or "gross") voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.*

[2] *The total number of exercisable at a shareholders' meeting (or "net") voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed.*

**Contacts**


*Nanobiotix*

**Communications Department**
*Brandon Owens*
*VP, Communications*
+1 (617) 852-4835
contact@nanobiotix.com

**Investor Relations Department**
*Joanne Choi*
*VP, Investor Relations (US)*
*+1 (713) 609-3150*
*Ricky Bhajun*
*Director, Investor Relations (EU)*
investors@nanobiotix.com

*Media Relations*

France – **HARDY**
Caroline Hardy
+33 06 70 33 49 50
carolinehardy@outlook.fr

Global – **uncapped**
Becky Lauer
+1 (646) 286-0057
uncappednanobiotix@uncappedcommunications.com


**Attachments**

- 20261112-Nanobiotix-PR_Voting_Rights_oct_2026 (https://ml.globenewswire.com/Resource/Download/381e0a63-40ff-4bce-993d-552bab7678b6)